These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264 [TBL] [Abstract][Full Text] [Related]
6. Systemic side effects of ophthalmic drops. Levy Y; Zadok D Clin Pediatr (Phila); 2004; 43(1):99-101. PubMed ID: 14968900 [TBL] [Abstract][Full Text] [Related]
7. Anterior uveitis as a side effect of topical brimonidine. Byles DB; Frith P; Salmon JF Am J Ophthalmol; 2000 Sep; 130(3):287-91. PubMed ID: 11020406 [TBL] [Abstract][Full Text] [Related]
8. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations. Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479 [TBL] [Abstract][Full Text] [Related]
9. Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma. Walters G; Taylor RH Eye (Lond); 1999 Dec; 13 ( Pt 6)():797-8. PubMed ID: 10707152 [No Abstract] [Full Text] [Related]
10. [The ocular hypotensive effect and safety of 0.2% brimonidine]. Yu M; Li Y; Ge J Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513 [TBL] [Abstract][Full Text] [Related]
11. The teardrop sign: a rare dermatological reaction to brimonidine. Scruggs JT; Whiteside-Michel J; Brodsky MC Br J Ophthalmol; 2000 Jun; 84(6):671-2. PubMed ID: 10896417 [No Abstract] [Full Text] [Related]
12. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma. Korsch E; Grote A; Seybold M; Soditt V Eur J Pediatr; 1999 Aug; 158(8):685. PubMed ID: 10445353 [No Abstract] [Full Text] [Related]
13. [Anterior uveitis and topical brimonidine: a case report]. Velasque L; Ducousso F; Pernod L; Vignal R; Deral V J Fr Ophtalmol; 2004 Dec; 27(10):1150-2. PubMed ID: 15687926 [TBL] [Abstract][Full Text] [Related]
14. Failure of naloxone to reverse brimonidine-induced coma in an infant. Sztajnbok J J Pediatr; 2002 Apr; 140(4):485-6; author reply 486. PubMed ID: 12006970 [No Abstract] [Full Text] [Related]
16. [Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety]. Kurysheva NI Vestn Oftalmol; 2019; 135(2):144-150. PubMed ID: 31215546 [TBL] [Abstract][Full Text] [Related]
17. Is brimonidine ophthalmic a safe therapy for infants? Daubert GP J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995 [TBL] [Abstract][Full Text] [Related]
18. Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine. Crichton AC Can J Ophthalmol; 1998 Aug; 33(5):254-5; discussion 257-8. PubMed ID: 9740952 [No Abstract] [Full Text] [Related]
19. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers. Mungan NK; Wilson TW; Nischal KK; Koren G; Levin AV J AAPOS; 2003 Feb; 7(1):69-70. PubMed ID: 12690374 [TBL] [Abstract][Full Text] [Related]
20. Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy. Lee JS; Kim CY Expert Rev Clin Pharmacol; 2022 Aug; 15(8):911-919. PubMed ID: 35951740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]